Ligand Pharmaceuticals Incorporated

NasdaqGM:LGND Stock Report

Mkt Cap: US$1.2b

We’ve recently updated our valuation analysis.

Ligand Pharmaceuticals Valuation

Is LGND undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LGND?

Other financial metrics that can be useful for relative valuation.

LGND key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5x
Enterprise Value/EBITDA21.1x
PEG Ration/a

Price to Sales Ratio vs Peers

How does LGND's PS Ratio compare to its peers?

The above table shows the PS ratio for LGND vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average19.7x
SCLX Scilex Holding
31.8xn/aUS$1.1b
AMYT Amryt Pharma
3.8x20.4%US$931.9m
AMPH Amphastar Pharmaceuticals
3.1x5.3%US$1.5b
ACRS Aclaris Therapeutics
39.9x40.3%US$936.9m
LGND Ligand Pharmaceuticals
5x3.6%US$1.2b


Price to Earnings Ratio vs Industry

How does LGND's PE Ratio compare vs other companies in the US Pharmaceuticals Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a10.2%
n/an/an/a


Price to Sales Ratio vs Fair Ratio

What is LGND's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LGND PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5x
Fair PS Ratio2.5x

Price-To-Sales vs Fair Ratio: LGND is expensive based on its Price-To-Sales Ratio (5x) compared to the estimated Fair Price-To-Sales Ratio (2.5x).


Share Price vs Fair Value

What is the Fair Price of LGND when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LGND forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$71.45
US$111.67
+56.3%
17.1%US$135.00US$90.00n/a6
Jan ’24US$66.80
US$111.67
+67.2%
17.1%US$135.00US$90.00n/a6
Dec ’23US$69.99
US$125.83
+79.8%
21.8%US$175.00US$95.00n/a6
Nov ’23US$84.61
US$149.17
+76.3%
10.1%US$175.00US$130.00n/a6
Oct ’23US$86.11
US$179.50
+108.5%
33.4%US$310.00US$130.00n/a6
Sep ’23US$94.07
US$181.17
+92.6%
33.1%US$310.00US$130.00n/a6
Aug ’23US$89.70
US$181.17
+102.0%
33.1%US$310.00US$130.00n/a6
Jul ’23US$90.58
US$182.50
+101.5%
32.6%US$310.00US$130.00n/a6
Jun ’23US$85.97
US$193.33
+124.9%
29.8%US$310.00US$130.00n/a6
May ’23US$92.86
US$195.43
+110.5%
27.9%US$310.00US$130.00n/a7
Apr ’23US$117.06
US$195.43
+66.9%
27.9%US$310.00US$130.00n/a7
Mar ’23US$97.80
US$195.43
+99.8%
27.9%US$310.00US$130.00n/a7
Feb ’23US$122.54
US$211.71
+72.8%
19.8%US$310.00US$180.00US$70.657
Jan ’23US$154.46
US$211.71
+37.1%
19.8%US$310.00US$180.00US$66.807
Dec ’22US$154.22
US$211.71
+37.3%
19.8%US$310.00US$180.00US$69.997
Nov ’22US$151.49
US$207.86
+37.2%
21.4%US$310.00US$170.00US$84.617
Oct ’22US$134.82
US$207.86
+54.2%
21.4%US$310.00US$170.00US$86.117
Sep ’22US$139.74
US$207.00
+48.1%
21.7%US$310.00US$170.00US$94.077
Aug ’22US$113.51
US$207.00
+82.4%
21.7%US$310.00US$170.00US$89.707
Jul ’22US$135.93
US$213.57
+57.1%
19.2%US$310.00US$180.00US$90.587
Jun ’22US$113.57
US$213.57
+88.1%
19.2%US$310.00US$180.00US$85.977
May ’22US$145.89
US$221.14
+51.6%
16.7%US$310.00US$198.00US$92.867
Apr ’22US$154.60
US$224.67
+45.3%
17.2%US$310.00US$198.00US$117.066
Mar ’22US$156.52
US$224.67
+43.5%
17.2%US$310.00US$198.00US$97.806
Feb ’22US$180.03
US$185.83
+3.2%
13.7%US$229.00US$146.00US$122.546


Discover undervalued companies